EAN 2025 | Microglial cell function in healthy controls versus epileptic patients: an in vitro model
Bárbara Guerra Leal, PhD, Porto University, Porto, Portugal, highlights a study using an in vitro model to understand microglial cell function in patients with epilepsy. Dr Leal highlights the differences in monocyte differentiation into microglia-like cells between healthy controls and patients with epilepsy. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I want to highlight our study with the in vitro model that we have. We have monocytes that we collect from peripheral blood, and we differentiate these monocytes with different growth factors and cytokines, including IL-34. We differentiate these monocytes into microglia-like cells, and we have a model, an in vitro model, that will help us to understand better the function of microglial cells in different environments...
Yeah, I want to highlight our study with the in vitro model that we have. We have monocytes that we collect from peripheral blood, and we differentiate these monocytes with different growth factors and cytokines, including IL-34. We differentiate these monocytes into microglia-like cells, and we have a model, an in vitro model, that will help us to understand better the function of microglial cells in different environments. Just to show you, we observe that monocytes from healthy controls and from epileptic patients differentiate differently into microglial-like cells, and these cells from controls are already in an activated state. So we believe that this could be particularly important not only for epilepsy, but for other immune conditions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
